Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

Journal of Clinical Investigation

Volumn 112, Issue 2, 2003, Pages 275-285

  Jumbe, Nelson ^a,b   Louie, Arnold ^a   Leary, Robert ^c   Liu, Weiguo ^b   Deziel, Mark R ^a   Tam, Vincent H ^a   Bachhawat, Reetu ^b   Freeman, Christopher ^b   Kahn, James B ^d   Bush, Karen ^e   Dudley, Michael N ^f   Miller, Michael H ^b   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f Essential Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; OFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIUM; DOSE RESPONSE; DRUG EXPOSURE; DRUG SENSITIVITY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VALIDATION PROCESS; ANIMAL; FEMALE; GRAM NEGATIVE INFECTION; INSTITUTE FOR CANCER RESEARCH MOUSE; KINETICS; METABOLISM; MONTE CARLO METHOD; MOUSE; MULTIDRUG RESISTANCE; MUTATION; PATHOGENICITY; THEORETICAL MODEL; TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; KINETICS; MICE; MICE, INBRED ICR; MODELS, THEORETICAL; MONTE CARLO METHOD; MUTATION; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLONES; TIME FACTORS;

EID: 0042743965     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200316814     Document Type: Article

References (30)

1. Eagle, H., Fleischman, R., and Levy, M. 1953 Continuous versus discontinuous therapy with penicillin: the effect of interval between injections on therapeutic efficacy. N. Engl. J. Med. 248:481-488.
2. Craig, W.A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibiotic dosing of mice and men. Clin. Infect. Dis. 26:1-10.
3. Craig, W.A. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl. 3):S233-S237.
4. Jourdain, B., et al. 1995. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am. J. Respir. Crit. Care Med. 152:241-246.
5. Lipsitch, M., and Levin, B.R. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363-373.
6. Blondeau, J.M., Zhao, X., Hansen, G., and Drlica, K. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
7. Zhou, J., et al. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutants. J. Infect. Dis. 182:517-525.
8. Drlica, K., Engle, E.C., and Manes, S.H. 1980. DNA gyrase on the bacterial chromosome: possibility of two levels of action. Proc. Natl. Acad. Sci. U. S. A. 77:6879-6883.
9. Paulsen, I.T., Brown, M.H., and Skurray, R.A. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608.
10. Munoz, R., and De La Campa, A.G. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
11. Nikaido, H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science. 264:382-388.
12. Ng, E.Y., Trucksis, M., and Hooper, D.C. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the fiqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
13. Lomovskaya, O., et al. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.
14. D'Argenio, D.Z., and Schumitzky, A. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, California, USA. http://bmsr.usc.edu/.
15. Wong, F.A., Juzwin, S.J., and Flor, S.C. 1997. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15:765-771.
16. Schumitzky, A., Jelliffe, R., and van Guilder, M. 1994. NPEM: a program for pharmacokinetic population analysis. Clin. Pharmacol. Ther. 55:163. (Abstr.)
17. Yamaoko, K., Nakagawa, T., and Uno, T. 1978. Application of Akaike's Information Criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.
18. Kureishi, A., Diver, J.M., Beckthold, B., Schollardt, T., and Bryan, L.E. 1994. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob. Agents Chemother. 38:1944-1952.
19. Nakano, M., et al. 1997. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2289-2291.
20. Lomovskaya, O., and Watkins, W. 2001. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J. Mol. Microbiol. Biotechnol. 3:225-236.
21. Drusano, G.L., et al. 2002. Target attainment analysis for levofloxacin 750 mg IV daily for nosocomial pneumonia using Monte Carlo simulation for common Gram-negative pathogens. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 25-29, 2002, San Diego, California, USA. American Society for Microbiology, Washington, DC, USA. Abstract A-638.
22. Chow, J., et al. 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115:585-590.
23. Kohler, T., Michea-Hamzehpour, M., Plesiat, P., Kahr, A.-L., and Pechere, J.-C. 1997. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2540-2543.
24. Drusano, G.L., Johnson, D.E., Rosen, M., and Standiford, H.C. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
25. Preston, S.L., et al. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 279:125-129.
26. Drusano, G.L., et al. 2001. Use of preclinical data for the choice of a Phase II/III dose for evernimicin with application to decision support for identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
27. Forrest, A., Ballow, C.H., Nix, D.E., Birmingham, M.C., and Schentag, J.J. 1993. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob. Agents Chemother. 37:1065-1072.
28. Peloquin, C.A., Cumbo, T.J., Nix, D.E., Sands, M.F., and Schentag, J.J. 1989. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentration and clinical condition on bacterial eradication. Arch. Intern. Med. 149:2269-2273.
29. Fink, M.S., et al. 1994. Treatment of severe pneumonia in hospitalized patients: results of a randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother 38:547-557.
30. Sindelar, G., et al. 2000. Mutation prevention concentration as a measure of fluoroquinolone potency against Mycobacteria. Antimicrob Agents Chemother 44:3337-3343.